Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Daclizumab Therapy for Multiple Sclerosis.
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.
Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).
Complex antibody profiling to predict clinical outcome in childhood ADS.
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA).
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures induced by pentylenetetrazol via protection of myelin sheath.
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
Visualization of myelination in GFP-transgenic zebrafish.
Clinically feasible MTR is sensitive to cortical demyelination in MS.
Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
The immunopathology of multiple sclerosis: an overview.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Cognitive impairment in multiple sclerosis.
Inflammation-induced fatigue: Exploring neurobiological mechanisms and potential treatments
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

Pages